BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Capecitabine: trial readouts and FDA decisions

9 upcoming industry Phase 2/3 readout(s) in the next 90 days, 0 upcoming FDA event(s), 12 readout(s) in the last 180 days and 0 FDA event(s) in the last 12 months. Sponsors: Qilu Pharmaceutical Co., Ltd., Sichuan Baili Pharmaceutical Co., Ltd., BeyondBio Inc., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., AskGene Pharma, Inc., Jiangsu HengRui Medicine Co., Ltd., Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., CStone Pharmaceuticals. Drug names come from ClinicalTrials.gov intervention names and FDA records, lightly normalised; one drug can appear under several names (code, generic, brand).

Upcoming trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11-30 est.P1/P2BeyondBio Inc.NCT05093907 A Study to Evaluate Safety and Efficacy of BEY1107 in Combination with Capecitabine in Patients with Metastatic Colorectal CancerMetastatic Colorectal Cancerrecruiting27
2026-12 est.P1/P2Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT06202261 A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast CancerMetastatic Breast Cancer; Recurrent Breast Cancer; Advanced Malignanciesrecruiting154
2026-12 est.P2Qilu Pharmaceutical Co., Ltd.NCT06942767 Combination of QLS31905, QL2107 and Chemotherapy as First-line Therapy in CLDN18.2-positive Unresectable Locally Advanced or Metastatic Gastric or GastroesophagGastric Adenocarcinoma; Gastroesophageal Junction Adenocarcinomanot yet recruiting100
2026-12-30 est.P3AskGene Pharma, Inc.NCT06206733 ASKB589 in Combination With CAPOX and PD-1 Inhibitor in Patients With Advanced or Metastatic GC/GEJ AdenocarcinomaGastroesophageal Junction Adenocarcinoma; Gastric Adenocarcinomaactive not recruiting780
2026-12-31 est.P3Jiangsu HengRui Medicine Co., Ltd.NCT05424835 A Trial of SHR-A1811versus Pyrotinib in Combination With Capecitabine in HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously TreatedHER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzactive not recruiting381
2026-12-31 est.P3Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. SKBBYNCT06081959 Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast CancerMetastatic Breast Cancerrecruiting376
2027-01 est.P1/P2CStone PharmaceuticalsNCT06741644 A Phase I/II Study of CS2009 in Participants With Advanced Solid TumorsAdvanced Solid Tumorsrecruiting800
2027-01-11 est.P3FutureGen Biopharmaceutical (Beijing) Co., LtdNCT06177041 M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable orLocally Advanced Unresectable or Metastatic Gastric Cancer; Locally Advanced Unresectable or Metastarecruiting486
2027-01-15 est.P2Biostar Pharma, Inc.NCT06764940 A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain MetastasesHER2-negative Breast Cancer Patients With Brain Metastasesrecruiting120

Readouts, last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11 est.P3Sichuan Baili Pharmaceutical Co., Ltd.NCT06118333 A Study Comparing BL-B01D1 With Physician's Choice of Chemotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma(PANKU-NPC01)Nasopharyngeal Carcinomaactive not recruiting386
2026-10 est.P2Qilu Pharmaceutical Co., Ltd.NCT07151872 Combination of QLS31905 and Chemotherapy ± QL2107 in Patients With CLDN18.2-positive Advanced Biliary Tract CancerCLDN18.2-positive Advanced Biliary Tract Cancernot yet recruiting120
2026-09-30 est.P2Convalife (Shanghai) Co., Ltd.NCT06374888 Nilatinib Maleate Tablets Combined With Capecitabine in the Treatment of HER2-positive Advanced Esophageal/Esophagogastric Junction/Gastric Adenocarcinoma With Her2-positive Advanced Esophageal/Esophagogastric Junction/Gastric Adenocarcinoma With Brain Metastanot yet recruiting28
2026-09 est.P3CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.NCT05717764 Clinical Study of Mitoxantrone Hydrochloride Liposome Injection Combined With Capecitabine Versus Capecitabine Monotherapy in Patients With Recurrent MetastaticRecurrent Metastatic Nasopharyngeal Carcinomanot yet recruiting500
2026-08-28P3Arcus Biosciences, Inc. RCUSNCT05568095 A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That CAdvanced Upper Gastrointestinal Tract Adenocarcinomacompleted1040
2026-08-18 est.P3Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.NCT06519370 FDA018-ADC vs Investigator's Choice Chemotherapy to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast CancerTriple Negative Breast Canceractive not recruiting350
2026-08-12P3DualityBio Inc.NCT06018337 A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)Metastatic Breast Canceractive not recruiting541
2026-08 est.P3Sichuan Baili Pharmaceutical Co., Ltd.NCT06343948 A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+HER2- Breast CancHR+HER2- Breast Canceractive not recruiting383
2026-07-29P2Processa Pharmaceuticals PCSANCT06568692 A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast CancerBreast Cancer; TNBC - Triple-Negative Breast Cancer; HER2-negative Breast Cancerterminated20
2026-07-15P3Jazz Pharmaceuticals JAZZNCT05152147 A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Gastric Neoplasms; Gastroesophageal Adenocarcinoma; Esophageal Adenocarcinomaactive not recruiting920
2026-06-30 est.P2Qilu Pharmaceutical Co., Ltd.NCT06446388 Study of QLS31905 and/or QL1706 Combination With Chemotherapy in the Advanced Malignant Solid TumorsAdvanced Solid Tumornot yet recruiting360
2026-06 est.P1/P2CG Pharmaceuticals, IncNCT05249101 A Study of Ivaltinostat Plus Capecitabine or Capecitabine in Metastatic Pancreatic AdenocarcinomaMetastatic Pancreatic Adenocarcinomaactive not recruiting70

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.